Quiver Bioscience key facts
as of Oct 2026- Developer of a neuroscience research platform designed to accelerate the discovery of therapeutics for central nervous system disorders.
- Quiver Bioscience is valued at approximately $29.0M as of Oct 2026 (last reported valuation).
- It has raised $54.4M; the latest was Later Stage VC in Apr 2026.
- Notable investors include Pimlico Pond Investments, Exponential Capital (Atlanta), National Institutes of Neurological Disorders and Stroke, Porta (Beverages).
- Status: Privately Held (backing).
Quiver Bioscience's last reported valuation, Nov 2018. Nothing priced has surfaced since.
- ·Watch Quiver Bioscience: the Monday email on marks, rounds and moves
Quiver Bioscience funding rounds
No funding rounds for Quiver Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Quiver Bioscience valuation
Quiver Bioscience's last reported valuation was $29 million in Nov 2018. No priced round, secondary trade or fund mark has surfaced since.
Quiver Bioscience investors
4 investors are on record for Quiver Bioscience, including Pimlico Pond Investments, Exponential Capital (Atlanta), National Institutes of Neurological Disorders and Stroke and Porta (Beverages).
About Quiver Bioscience
Developer of a neuroscience research platform designed to accelerate the discovery of therapeutics for central nervous system disorders. The company offers advanced human cellular models, measurement engineering, and artificial intelligence-driven analysis for neuronal activity and drug response, enabling life sciences researchers and pharmaceutical organizations to identify and develop therapeutics for chronic pain and neurodevelopmental disorders.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2013
- Employees
- 26
- Website
- quiverbioscience.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.